|
Poolbeg Pharma PLC - London-based biopharmaceutical firm focused on cancer immunotherapy - Raises £3.5 million from a placing of 58.3 million new shares at 6 pence each. The placing price is a discount of 16% from the stock’s closing market price on Monday. The funds will be used to fund two drug trials through to completion, extending Poolbeg’s cash runway into the second quarter of 2028. The share placing is run by broker Oak Securities. ‘This successful fundraise is a great market endorsement of Poolbeg, our strategy and pipeline,’ says Chief Executive Officer Jeremny Skillington. ‘Not only does it extend our expected cash runway into Q2 2028, but it strengthens the company’s position in ongoing partnering discussions.’ Poolbeg late last month said it received a patent in South Africa that will protect its POLB 001 treatment, used for the prevention of hypercytokinaemia and severe influenza, until December 2038. Current stock price: 6.05p, closed down 14% in London on Tuesday for a £41.2 million market capitalisation 12-month change: up 92% Copyright 2026 Alliance News Ltd. All Rights Reserved.
|
